Triaziquone

Triaziquone

SCHEMBL975384

NC(=O)NC(N)=O.O=C1C=C(N2CC2)C(=O)C(N2CC2)=C1N1CC1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 1/20 0.38
HTT P42858 2/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
STAT3 P40763 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NSD2 O96028 3/20 0.32
APAF1 O14727 2/20 0.32
TDP2 O95551 2/20 0.32
HKDC1 Q2TB90 2/20 0.32
TTR P02766 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
HIF1A Q16665 1/20 0.31
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triaziquone SCHEMBL738610 0.90 DNMT1 (0.42) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL20359693 0.85 DNMT1 (0.39) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL4608905 0.84 DNMT1 (0.43) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL8303 0.84 DNMT1 (0.48) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL8926769 0.82 DNMT1 (0.42) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL10906735 0.82 HTT (0.43) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL7783197 0.82 MAPT (0.46) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL149876 0.82 MAPT (0.46) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL1975651 0.82 DNMT1 (0.37) DNMT1HTTTP53MAPTSTAT3
Triaziquone SCHEMBL22716451 0.82 HTT (0.38) DNMT1HTTTP53MAPTSTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1711506-B1 SYNTHESIS OF BIURETS AND ISOCYANATES WITH ALKOXYSILANE FUNCTIONS, FORMULATIONS CONTAINING SAME AND USE THEREOF VENCOREX FRANCE (FR) 2014-10-08 EP disclosed
US-8173742-B2 Synthesis of biurets and isocyanates with alkoxysilane functions, formulations containing same and use thereof PERSTORP FRANCE (FR) 2012-05-08 US disclosed
US-20110065957-A1 SYNTHESIS OF BIURETS AND ISOCYANATES WITH ALKOXYSILANE FUNCTIONS, FORMULATIONS CONTAINING SAME AND USE THEREOF PERSTORP FRANCE (FR) 2011-03-17 US disclosed
US-7875693-B2 reacting hexamethylene diisocyanate with aminopropy/ltrimethoxysilane/3-/ to form intermediate isocyanatoalkylsilane and reacting the isocyanatoalkylsilane with an isocyanate to form a biuret PERSTORP FRANCE (FR) 2011-01-25 US disclosed
US-20070015895-A1 Synthesis of biurets and isocyanates with alkoxysilane functions, formulations containing same and use thereof RHODIA OPERATIONS (FR) 2007-01-18 US disclosed
EP-1711506-A2 SYNTHESIS OF BIURETS AND ISOCYANATES WITH ALKOXYSILANE FUNCTIONS, FORMULATIONS CONTAINING SAME AND USE THEREOF RHODIA CHIMIE (FR) 2006-10-18 EP disclosed
WO-2005070942-A2 SYNTHESIS OF BIURETS AND ISOCYANATES WITH ALKOXYSILANE FUNCTIONS, FORMULATIONS CONTAINING SAME AND USE THEREOF RHODIA CHIMIE (FR) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065957-A1 SYNTHESIS OF BIURETS AND ISOCYANATES WITH ALKOXYSILANE FUNCTIONS, FORMULATIONS CONTAINING SAME AND USE THEREOF THEM6, INMT, BCAT2 DNMT1 1454/4885HTT 1555/4885TP53 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.